Thrombohaemorrhagic syndrome in patients with a myeloproliferative disease with thrombocythemia

Česká verzia

Authors: M. Penka ¹; J. Kissová ¹; A. Buliková ¹; J. Zavřelová ¹; J. Ovesná ¹; T. Pavlík ²
Authors place of work: Oddělení klinické hematologie FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Miroslav Penka, CSc. ¹; Institut biostatistiky a analýz Lékařské a Přírodovědecké fakulty MU Brno, vedoucí pracoviště doc. RNDr. Ladislav Dušek, Ph. D. ²
Published in the journal: Vnitř Lék 2011; 57(3): 306-311
Category: 60th birthday of prof. Mudr. Jiřího Vítovce, CSc, FESC

Summary

Thrombohaemorrhagic syndrome is a clinical syndrome manifesting with concurrent bleeding and thrombosis. It is associated with a range of pathological states, typically with myeloproliferative diseases, paraproteinaemia, liver disease as well as disseminated intravascular coagulation and similar syndromes (so called DIC-like syndrome). Thrombohaemorrhagic syndrome might be a symptom of chronic myeloproliferations, particularly if these are associated with thrombocythemia. It is most frequently linked to essential thrombocythemia. However, in this disease, it seems that the clinical symptoms of bleeding and thrombosis might not be directly determined by the number of platelets, as it would suggest itself, but that this can be consequent to other changes. These may include predisposition to thrombophilia, cardiovascular risk, leukocytosis etc. as well as, for example, platelet dysfunction. The present study focuses on platelet dysfunction in conjunction with clinical symptoms of bleeding and thrombosis.

Key words:
thrombohaemorrhagic syndrome – thrombosis – bleeding – myeloproliferation – thrombocythemia

Zdroje

1. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–232.

2. Brière JB. Essential thrombocythemia. Review. Orphanet J Rare Dis 2007; 2–3: 1–17.

3. Carobbio A, Antoniovi E, Guglielmelli P et al. Leukocytosis and risk stratification assesment in essential trhobmocythemia. J Clin Oncol 2008; 26: 2732–2736.

4. Falanga A, Marchetti M, Vignoli A et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523–530.

5. Gruppo Italiano Studio Policitemia. Polycythemia Vera: The NaTURAL History of 1 213 Patients Folowed for 20 Years. Ann Intern Med 1995; 123: 656–664.

6. Jensen MK, de Nully Brown P, Lund BV et al. Increase platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110: 116–124.

7. Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: Pathogenetic mechanism and prevention. Best Pract Res Clin Haematol 2006; 19: 617–633.

8. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Spotlight review. Leukemia 2008; 22: 2020–2028.

9. Messa RA. Navigating the Evolving Paradigms in the Diagnosis and Treatment of Myeloproliferative Disorders. Hematology Am Soc Hematol Educ Program 2007; 92: 355–362.

10. Michiels JJ, Berneman Z, Schroyens W et al. Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and by coumadin. Blood Cells Mol Dis 2006; 36: 199–205.

11. Passamonti F, Rumi E, Arcaini L et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in Essentials trhombocythemia: a study of 605 patients. Haematologica 2008; 93: 1645–1651.

12. Penka M, Schwarz J, Pytlík R et al. Doporučený postup diagnostiky a terapie esenciální trombocytemie a trombocytemie provázející myeloproliferativní onemocnění. Vnitř Lék 2005; 51: 741–751.

13. Penka M, Schwarz J, Ovesná P et al. Esenciální trombocytemie a jiné myeloproliferace s trombocytemií léčené Thromboreductinem. Výstupy z databáze Registru k prvnímu čtvrtletí roku 2010. Vnitř Lék 2010; 56: 503–512.

14. Petrides PE, Siegel F. Thrombotic complications in essential trhombocythemia (ET): Clinical Facts and biochemical riddles. Blood Cells Mol Dis 2006; 36: 379–384.

15. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interactions. Semin Hematol 1997; 34: 171–187.

16. Ruggeri M, Gisslinger H, Tosetto A et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71: 1–6.

17. Schwarz J, Hrachovinova I, Vorlova Z et al. Thromboembolism in thrombocythemia patients with an additional thrombophilic state. (Abstr. 974). Hematol J 2004; 5 (Suppl 2): S321.

18. StatSoft, Inc. (2009). STATISTICA (data analysis software system), version 9.0. www.statsoft.com

19. Vannucchi AM, Guglielmelli P, Teffer A. Advances in Understanding and Management of Myeloproliferative Neoplasms. Cancer J Clin 2009; 59: 171–191.

20. Wu KK. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978; 88: 7–11.